01 January 2012: Special Report
Use of individual auto-injector kits ‘IZAS-05’ on the contemporary battlefield
Radosław Ziemba
DOI: 10.12659/MSM.882188
Med Sci Monit 2012; 18(1): SR1-8
Background
Nowadays, the most likely use of chemical warfare agents (CWAs) can take place during a terrorist attack. Depending on their effect on the human body, there are mainly nerve toxic agents, such as: sarin, soman and VX, and blister toxic agents, such as yperite and lewisite. It seems that terrorists rarely make use of incapacitating toxic agents, which cause only short, transient disturbances in human psyche and motor activity [1–3]. They can be exemplified by psychogases, such as LSD-25 and BZ, as well as irritants (tear gasses), such as CS, CN and CR, employed by the police to incapacitate and harass for a short time [1,4,5].
The most toxic among chemical warfare agents are the derivatives of organophosphorus compounds. Even small doses of these substances cause clinical poisoning accompanied by the syndrome of muscarinic-like and nicotinic-like symptoms, as well as central nervous system symptoms. Poisoning symptoms develop instantly, thus necessitating application of adequate treatment, frequently including intensive care.
The Table 1 below shows human toxicity of some chemical warfare agents [1,6].
The importance of immediate administration of an antidote is proved by the fact that the half-life of ‘aging’ of the enzyme-organophosphorus compound complex is very short, e.g.: for AChE (acetylcholinesterase)-soman complex it is only 3.5 minutes, while for AChE-sarin – about 18 minutes. This means that after this time only 50% of the blocked enzyme can be reactivated. What is extremely important is also the knowledge that most CWAs show good or very good sorptive properties and ability to penetrate various materials (wood, rubber, fabric, skin and the like). Thus, materials contaminated with chemical warfare agents are a serious source of poisoning, even more so in shelters or isolated rooms [1–7,10].
In crisis situations, most frequently during transportation catastrophes or terrorist attacks, the most important thing is to organize and conduct rescue operations (in case of hazard to a larger number of people).
However, in many situations, particularly during warfare, the foundation of life protection is self-aid or buddy-aid (e.g.: in the event of loss of consciousness).
Due to the specific effect of chemical warfare agents on the human body, the above-mentioned treatment must be multidirectional, i.e. combined.
That is why individual auto-injector kits IZAS-05 [11], which have been included in the equipment of the Polish soldier for several years, contain [12,13]:
Observation of warfare in Iraq and Afghanistan, as well as talks with soldiers, and in particular with medical aids, prove that especially in the case of mass poisoning with CWAs, where – as has already been said – the most vital role is played by the time of antidote administration [14], it becomes necessary to equip medical rescuers with so-called masks with active filters. They allow free performance of the activities connected with organizing and conducting rescue operations for 30–60 minutes, depending on which CWA has been used. This seems to be the minimum time needed to leave the contaminated zone.
1. Individual auto-injector kit IZAS-05
1.1. COMPONENTS OF IZAS-05:
An individual auto-injector kit IZAS-05 comprises the following auto-injectors:
2. General principles concerning auto-injectors
2.1. PRINCIPLE OF OPERATION OF AUTO-INJECTORS:
An auto-injector has a container with drugs (antidotes). Once the triggering mechanism is released, the needle comes out automatically and is inserted into the body (into the muscles, at the site where an auto-injector is positioned) [3].
The drugs are injected into the body via the needle introduced into the muscles. Drug administration, that is complete emptying of the drug container, takes up to 10 seconds at the most.
Insertion of the needle is usually accompanied by slight pain, comparable to the one experienced when given an intramuscular injection in hospital to administer a drug, or during the blood drawing procedure.
3. Usage of auto-injectors
3.1. PREPARING AN AUTO-INJECTOR FOR USE:
Remove the auto-injector from the outer protecting packaging directly before use – Figure 1 (by pressing the case safety catch or unscrewing the tube cap).
Hold the auto-injector in the hand that is used for most activities – Figure 2 (right hand if you are a right-handed person). If the dominant hand is injured, use the auto-injector with the healthy (fit) hand.
3.2. POSITIONING THE AUTO-INJECTOR FOR INJECTION:
The needle end of the auto-injector should be positioned against the injection site and pressed hard enough for the skin to dent slightly at the site where the auto-injector is positioned.
Position the auto-injector perpendicularly (at the angle of 90 degrees) against the body surface. Incorrect positioning of the auto-injector while administering the drug can result in its damage or failure to administer the dose. Correct positioning of the auto-injector is shown in Figure 3.
While injecting, the auto-injector must not be detached from the body surface.
3.3. INJECTION SITE:
An auto-injector is designed for administering drugs both directly through bare skin (without clothing), and indirectly – through the field gear. In the event of poisoning with nerve CWAs, due to – among others – the necessity to administer antidotes immediately, the clothing should not be removed to uncover the skin at the injection site.
While administering drugs (antidotes), it is crucial that the auto-injector needle be inserted into a large muscle. There are two basic sites where drugs can be injected safely with the use of auto-injectors: the thigh and the buttock.
Injection into the thigh – Figures 4–6: position the auto-injector at midpoint of the thigh, against its antero-lateral surface. Injection at the specified site will not result in damage to the nearby bone.
Injection into the buttock – Figure 7: position the auto-injector at the outer upper quadrant of the buttock. Injection at the specified site will not result in damage to the nearby nerve – Figures 8 and 9.
3.4. DRUG ADMINISTRATION:
After positioning the auto-injector against the thigh or the buttock, release the triggering mechanism (by levering up the red safety catch with your thumb) in such a way so as not to detach the auto-injector from the body surface [4].
The drug is administered automatically, once the triggering mechanism is released. You should wait for about 10 seconds for the auto-injector to be emptied – Figure 10. While administering the drugs, the auto-injector must not be detached from the body surface or redirected.
After 10 seconds from release of the triggering mechanism, remove the auto-injector with a rapid movement, and put it aside safely, avoiding wounding with the needle.
4. Auto-injectors in CWAs poisoning
4.1. SEQUENCE OF USE OF AUTO-INJECTORS:
In the event of poisoning with nerve CWAs, the brown auto-injector with a yellow cap (containing atropine and pralidoxime) should be used first (see subchapters 4.4.1 and 4.5.2); then, additional doses of atropine should be given with the use of yellow auto-injectors (in accordance with the principles specified in subchapters 4.4.2 and 4.5.3), followed, if need be, by an anticonvulsant with the use of a grey auto-injector (in accordance with the principles specified in subchapters 4.4.3 and 4.5.4).
4.2. CLASSIFICATION OF POISONING WITH NERVE CWAS:
In order to simplify the principles for medical proceeding on the battlefield, a classification of poisoning has been introduced, whereby two main types have been identified according to severity: moderate poisoning, in the event of which the drugs can be self-administered by the injured (self-aid), and severe poisoning – where treatment must be provided by the buddy (buddy-aid) or medical staff [17].
POISONING PRESENTING WITH SYMPTOMS OF MODERATE INTENSITY (MODERATE POISONING):
Symptoms:
SEVERE COURSE POISONING (SEVERE POISONING):
Symptoms:
4.3.1. GREEN AUTO-INJECTOR (TWO DRUGS: ATROPINE AND PRALIDOXIME):
In case of symptoms of poisoning with nerve CWAs (symptoms listed above), use the green auto-injector (atropine and pralidoxime).
If the poisoning symptoms are greatly intensified (severe poisoning – as described in 4007), the poisoned person is not able to self-inject the drugs. In such a situation, it is necessary that they be administered by another soldier who is around (buddy-aid).
4.3.2. YELLOW AUTO-INJECTOR (ATROPINE):
The yellow auto-injector contains an additional dose of atropine. An additional dose of atropine should be administered if the symptoms of poisoning with nerve CWAs (described in 4006 and 4007) occur after 10–15 minutes from administration of the previous dose of atropine with the use of the brown or yellow auto-injector (self-assessment and/or buddy-assessment).
4.3.3. GREY AUTO-INJECTOR (DIAZEPAM):
Diazepam (an anticonvulsant) is administered only in buddy-aid. A contaminated person with only moderately intensified symptoms of poisoning does not need an anticonvulsive drug, whereas a heavily poisoned person generally will not be able to self-administer the drug.
4.4. PRINCIPLES FOR USE OF AUTO-INJECTORS IN BUDDY-AID:
First, one should rescue oneself, then one can start rescuing others. Auto-injectors can be used for rescuing other soldiers (buddy-aid), who are not able to self-administer the drugs due to sustained injuries or intensified symptoms of poisoning.
In buddy-aid, auto-injectors from the rescued person’s kit are to be used as first, then, from the rescuer’s own kit or the kit belonging to a casualty or a person who has not been poisoned. Prior to using the auto-injector, the injured person should have a gas mask put on.
4.4.1. BROWN AUTO-INJECTOR WITH A YELLOW CAP (TWO DRUGS: ATROPINE AND PRALIDOXIME):
In case of symptoms of poisoning with nerve CWAs (symptoms listed above), use the brown auto-injector with a yellow cap (atropine and pralidoxime).
4.4.3. YELLOW AUTO-INJECTOR (ATROPINE):
A yellow auto-injector with an additional dose of atropine should be administered if:
An additional dose of atropine should not be administered if after 5–10 minutes from administration of the previous dose of atropine the poisoned person experiences significant increase in the heart rate (rapid heartbeat) and mouth dryness [3].
4.4.3. GREY AUTO-INJECTOR (DIAZEPAM):
An auto-injector with diazepam is to be used if:
5. Auto-injector with an analgesic
5.1. PRINCIPLES FOR USE OF THE AUTO-INJECTOR:
The auto-injector for first-aid on the battlefield contains 20 mg of morphine sulphate. The auto-injector is to be used if severe (‘difficult to bear’) pain occurs following a severe injury (e.g. extensive wounds, fractures). Usually, after several or a dozen or so minutes from use of the auto-injector the pain subsides or its intensity is reduced.
Persons in whom pain evidently does not subside within 30 minutes from first administration of morphine can receive an additional dose of the drug.
5.2. CONTRAINDICATIONS:
Auto-injectors with an analgesic must not be used in persons who are hypersensitive (allergic) to morphine. Auto-injectors with an analgesic should not be used for mild (‘slight’) pain accompanying an injury.
Use of alcohol after administration of morphine can intensify adverse drug reactions.
5.3. GENERAL NOTICE:
Morphine is a strong-acting drug. Use of auto-injectors inconsistently with the principles can cause loss of combat ability and adversely affect the soldier’s health.
Conclusions
Any equipment for emergency first treatment inevitably creates the need for optimum compromise between supply on the spot of accident or illness and portability. The aim of the procedure for the onsite treatment is not definitive, but the liquidation of a life threatening condition and prepare the patient for transport. Medical personnel should be familiar with the types of drugs and indications and contraindications for their use in patients. As a rule, selecting the drug should only be used when the dosage is known from experience. It is especially recommended clear ordering of drugs and possibly marking them as directed, to avoid any mistreatment. The pre-filled syringes were used during World War II to the administration, even on the battlefield, analgesics (e.g. morphine) wounded soldiers. The pre-filled syringes are used when there is a need to provide the drug in a small volume and an accurately measured dose to the patient so that they could do themselves, especially during combat operations. Auto-injectors of analgesic should not be used in patients who are hypersensitive (allergic) to morphine. An auto-injector of analgesic can not be used when the pain associated with trauma is negligible (“slight pain”). Morphine is a potent drug. Application of an auto-injector inconsistent with the principles may result in loss of combat capability of the soldier and adversely affect his health. The army used auto-injectors to inject into the body some drugs to prevent poisoning toxic warfare agents such as pralidoxime and other oximes, atropine, diazepam and analgesics such as morphine.
References
1. Romano JA, Lukey BJ, Salem HChemical Warfare Agents: Chemistry Pharmacology, Toxicology and Therapeutics, 2008, CRC Press
2. Shapira SC, Hammond JS, Cole LA: Essentials of Terror Medicine, 2009, Springer, Science + Business Media LLC
3. Thiermann H, Kehne K, Steinritz D: Red Blood Cell Acetylcholinesterase and Cholinesterase Status: Important Tools for the Physician in a Nerve Agent Scenario, Bundeswehr Institute of Pharmacology and Toxicology
4. Lallement G, Clair P, Zabe D, A new auto-injector for emergency self-treatment of nerve gas poisoning with and improved pharmaceutical concept and design
5. : Role of Oximes in the Treatment of Anticholinesterase Agent Poisoning, 1996, Oxford
6. Malloy CD: A History of Biological and Chemical Warfare and Terrorism, 2001, Gaithersburg, Maryland, Aspen Publishers
7. Eyer P, The role of oximes in the management of organophosphorus pesticide poisoning: Toxicol Rev, 2003
8. Bajgar J: Development of antidotes against nerve agents in Czech Republic, 2009, ASA Inc
9. Bajgar J, Fusek J, Kuca K, Treatment of organophosphate intoxication using cholinesterase reactivators: facts and fiction: Mini-Rev Med Chem, 2007
10. Ellison DH: Chemical and Biological Warfare Agents, 2008, CRC Press
11. Arena JM, Poisoning: Toxicology, Symptoms, Treatments
12. : First Aid – Field Manual, 2009, Washington, Department of The Army, The Navy and Air Force of USA
13. Fusek J, Bajgar J, Kassa J, Vachek J: Present antidotal means against chemical warfare agents in the Czech Army, Hradec Králové, Czech Republic, Military Medical Academy, Dept. of Toxicology
14. Wright L, Pope C, Liu J, The nervous system, as a target for chemical warfare agents: Chapter 32 Handbook of Toxicology of Chemical Warfare Agents, 2009, Elsevier – Academic Press
15. Melnick AL: Biological, Chemical, and Radiological Terrorism, 2008, Springer Science + Business Media LLC
16. Marrs TC, Maynard RL, Sidell FR: Chemical Warfare Agents – Toxicology and Treatment, 2007, John Wiley & Sons, Ltd
17. Thiermann H, Worek F, Reiter G, Modern strategies in therapy of organophosphate poisoning: Toxicoll Lett, 1999
In Press
Clinical Research
Institutional and Regional Variations in Access to Clinical Trials and Next-Generation Sequencing in Turkis...Med Sci Monit In Press; DOI: 10.12659/MSM.951027
Clinical Research
Low-Intensity Blood Flow-Restricted Multi-Joint Exercise Improves Muscle Function in Patients With Patellof...Med Sci Monit In Press; DOI: 10.12659/MSM.950516
Review article
Musculoskeletal Ultrasound and MRI in the Evaluation of Chemotherapy-Induced Peripheral Neuropathy: A ReviewMed Sci Monit In Press; DOI: 10.12659/MSM.951283
Clinical Research
Sensory Processing, Dissociation, and Affective Symptoms in Misophonia: A Cross-Sectional Study of 35 AdultsMed Sci Monit In Press; DOI: 10.12659/MSM.950938
Most Viewed Current Articles
17 Jan 2024 : Review article 10,187,196
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
13 Nov 2021 : Clinical Research 3,708,487
Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...DOI :10.12659/MSM.932788
Med Sci Monit 2021; 27:e932788
14 Dec 2022 : Clinical Research 2,341,643
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research 706,524
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387






